IXICO plc >GBP2m contract extension win - Huntington's disease (3623A)
29 Septiembre 2020 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 3623A
IXICO plc
29 September 2020
IXICO plc
("IXICO" or the "Company")
>GBP2m contract extension win in Huntington's disease
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience , has executed a c. GBP2m contract to
provide additional imaging services that will support a pivotal
Huntington's disease (HD) study. This builds on the Company's
existing contract to support our 'top-20' pharma client's Phase III
study in HD.
This contract does not have significant impact on management's
expectations of performance for the coming year, but will
contribute to the Company's already strong order book for next
year.
Giulio Cerroni, Chief Executive Officer of IXICO, commented: "We
are delighted that our client has chosen to expand our partnership
to support its study extension for Huntington's disease. This
decision validates our technology and endorses the service provided
as we help our clients throughout the trial pathway. IXICO is proud
to support the development of treatments for this devastating rare
disease."
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd Tel: + 44 ( 0)20 7933 8780 or IXICO@walbrookpr.com
Paul McManus / Lianne Cawthorne
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
mission is to transform the progression of our biopharmaceutical
clients' neurological therapeutic pipelines through the application
of novel imaging and digital biomarkers.
IXICO's data analytics services are used by the global
biopharmaceutical industry to interpret data from brain scans and
digital biosensors to enable better trial design, site
qualification, patient selection and clinical outcomes. We provide
technology-enabled services across all phases of clinical
evaluation. Our integrated digital platform provides a scalable and
secure infrastructure for the capture and analysis of regulatory
compliant clinical data to enable clients to make rapid, better
informed decisions. IXICO is also collaborating with partners to
develop new analytical techniques and companion digital health
products targeted at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTEAPNPAFSEEFA
(END) Dow Jones Newswires
September 29, 2020 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De May 2023 a May 2024